ASP Isotopes Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ASP Isotopes Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.85M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $4.14M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $433.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 10, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.41M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.60M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $139.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 10, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($159.84M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($32.42M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($16.29M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.95M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($2.61M) | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.91M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($26.35M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($16.04M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.10M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($2.61M) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.36M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $3.14M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $764.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.27M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $41.6K | Mar 31, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $2.60M | Apr 10, 2026 |
| FY2025 | Mar 31, 2024 | $500.0K | Apr 10, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($37.78M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($16.70M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($5.41M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.94M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($577.7K) | Mar 31, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.65M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $9.68M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $2.33M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.47M | Apr 10, 2024 |
| FY2024 | Jul 31, 2022 | 6.00M | Mar 31, 2025 |
| FY2022 | Dec 31, 2021 | $2.99M | Mar 31, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $498.02M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $94.35M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $27.54M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.50M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $7.14M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $235.12M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $43.18M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $8.71M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.68M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $1.14M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $204.15M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $47.90M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $16.30M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $9.82M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $6.00M | Mar 31, 2023 |
| FY2022 | Sep 13, 2021 | $0 | Mar 31, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.57M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $3.17M | Apr 10, 2026 |
| FY2025 | Dec 31, 2023 | $3.27M | Apr 10, 2026 |
| FY2024 | Oct 31, 2023 | $3.21M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 10, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($231.27M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($56.17M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($23.84M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.55M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($2.61M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $285.60M | Apr 10, 2026 |
| FY2024 | Dec 31, 2024 | $61.90M | Mar 31, 2025 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.36M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $2.38M | Apr 10, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 31, 2023 |
| FY2023 | Dec 30, 2022 | 0 | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 111.68M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 72.07M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 48.92M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 35.91M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | 20.65M | Mar 31, 2023 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $2.78M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |